Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc., a pharmaceutical company specializing in kidney disease treatments, has announced plans to reprice over a million common share purchase warrants issued through past private placements to a new exercise price of USD $5.00 per share. The repricing is subject to warrant holder acceptance and regulatory approval, and includes an acceleration clause if the company’s share price exceeds USD $6.50 over a sustained period. This strategic move could potentially make the warrants more attractive to investors and affect the company’s stock performance.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
